Press Releases

Relation Therapeutics, a leader in the use of high-resolution biology, machine learning and clinical insights to discover life-changing medicines, announced today the opening of their flagship integrated wet–dry laboratory. The laboratory and offices comprise 5,500 sq ft, located at the heart of London’s Knowledge Quarter, in close reach of collaborators and partners including globally renowned academic research centres and major pharma companies. Over the last year the company ha

Shionogi & Co., Ltd. today, at the 30th Conference on Retroviruses and Opportunistic Infections (CROI), presented further results from the Phase 3 part of the pivotal SCORPIO-SR trial (Phase 2/3 study) conducted in Japan, South Korea, and Vietnam (hereafter, the “Study”) of the novel COVID-19 oral antiviral ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622, hereafter “ensitrelvir”). Shionogi also presented exploratory data from the Study evalu

Antech Diagnostics, North America’s largest network of veterinary diagnostic reference laboratories, today announced that KeyScreen™ GI Parasite PCR will detect a new mutation for treatment-resistant canine hookworm by mid-April. KeyScreen is a molecular diagnostic test that detects 20 intestinal parasites in cats and dogs, including Giardia with zoonotic potential and treatment-resistant canine hookworm.     Following researchers’ discovery of a new

Dalton Pharma Services today announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility to fill vials, syringes, and cartridges under isolator technology. The sterile fill line is fully integrated with a new cGMP lyophilizer, providing complete sterile finished dosage form manufacturing capabilities for customers. The

HYTN Innovations Inc., a leading manufacturer of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids, is pleased to provide an update on its Active Pharmaceutical Ingredient (API) portfolio. The Company's Kelowna, B.C. facility holds all available licenses and amendments under both the Cannabis Act and the Controlled Drugs and Substances Act, enabling it to be at the forefront of regulatory compliance. As noted in previous news releases the

Piramal Pharma Solutions, a patient-focused Contract Development and Manufacturing Organization and part of Piramal Pharma Ltd  today announced that it has commenced production of initial batches of active pharmaceutical ingredients (APIs) in new reactor suites at its Riverview, Michigan , USA Construction of the capacity expansion at Riverview , known as Project PRIME (Piramal Riverview Integrated Manufacturing Expansion) Phase 1, broke ground in May 2021. Initial production i

Lantern Pharma Inc. a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced expansions and updates to RADR®’s product roadmap, which will further enhance its oncology drug discovery capabilities. These RADR® advancements will focus on additional innovative AI and ML approaches to develop Antibody Drug Conju

Univar Solutions Brasil Ltda., a subsidiary of Univar Solutions Inc. leading global solutions provider to users of specialty ingredients and chemicals, today announced a distribution agreement with SI Group for Ibuprofen, an active pharmaceutical ingredient (API) used to produce ibuprofen drugs for the pharmaceutical market. "Our strategic relationship with SI Group provides customers in Brazil access to a robust portfolio of innovative specialty ingredients and supply products in

BioDuro-Sundia has recently completed Discovery capability expansions of more than 100K ft2 of laboratory space within three different R&D Centers Dr. Xiang Li, President of BioDuro-Sundia Drug Discovery, explains: “At BioDuro-Sundia, we are fully invested in our clientele and pro-actively planning ahead to meet their needs. A few highlights of this expansion include: Discovery Biology department: Enlarged HCS capability Developed mo

The German drug manufacturer URSAPHARM has digitized the management of its contracts with the software Fabasoft Contracts. The company currently stores more than 9,000 contract documents in a highly secure database and manages them there in one place. The responsible employees are thus always informed about the status of all contracts - and the resulting obligations, changes and deadlines. Compliance with data protection and compliance requirements is also ensured. " Thanks to